Generic Name: daunorubicin (DAW noe ROO bi sin)
Brand Names: Cerubidine
What is daunorubicin?
Daunorubicin is a cancer (antineoplastic) medication. Daunorubicin interferes with the growth of cancer cells and slows their growth and spread in the body.
Daunorubicin is used in the treatment of leukemia (blood cancer).
Daunorubicin may also be used for purposes other than those listed in this medication guide.
What is the most important information I should know about daunorubicin?
Daunorubicin should only be administered under the supervision of a qualified healthcare provider experienced in the use of cancer chemotherapeutic agents.
Serious side effects have been reported with the use of daunorubicin including: allergic reactions (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives); severe heart damage with prolonged use; decreased bone marrow function and blood problems (extreme fatigue; easy bruising or bleeding; black, bloody or tarry stools; fever or chills; or signs of infection); severe nausea, vomiting, diarrhea, and loss of appetite; and others. Talk to your doctor about the possible side effects from treatment with daunorubicin.
What should I discuss with my healthcare provider before using daunorubicin?
Do not use daunorubicin without first talking to your doctor if you have
- kidney disease;
- liver disease;
heart disease;
poor bone marrow function;
received radiation therapy that encompassed the heart; or
previously received treatment with doxorubicin (Adriamycin, Rubex), doxorubicin liposomal (Doxil), daunorubicin (Cerubidine), daunorubicin liposomal (DaunoXome), idarubicin (Idamycin), or mitoxantrone (Novantrone).
The use of daunorubicin may be dangerous if you have any of the conditions listed above.
Daunorubicin is in the FDA pregnancy category D. This means that daunorubicin is known to be harmful to an unborn baby. Do not use daunorubicin without first talking to your doctor if you are pregnant. Discuss with your doctor the appropriate use of birth control during treatment with daunorubicin if necessary. Daunorubicin passes into breast milk and may harm a nursing baby. Breast-feeding should be avoided during treatment with daunorubicin. Children have an increased risk of heart problems due to treatment with daunorubicin. Growth and gonadal development may also be affected.
How should I use daunorubicin?
Daunorubicin should only be administered under the supervision of a qualified healthcare provider experienced in the use of cancer chemotherapeutic agents.
Your doctor will determine the correct amount and frequency of treatment with daunorubicin depending upon the type of cancer being treated and other factors. Talk to your doctor if you have any questions or concerns regarding the treatment schedule.
Your doctor will probably want you to have regularly scheduled blood tests and other medical evaluations during treatment with daunorubicin to monitor progress and side effects.
Skin accidentally exposed to daunorubicin should be rinsed thoroughly with soap and warm water.
Your healthcare provider will store daunorubicin as directed by the manufacturer. If you are storing daunorubicin at home, follow the directions provided by your healthcare provider.
What happens if I miss a dose?
Contact your doctor if you miss a dose of daunorubicin.
What happens if I overdose?
If for any reason an overdose of daunorubicin is suspected, seek emergency medical attention or contact your healthcare provider immediately.
Symptoms of a daunorubicin overdose tend to be similar to side effects caused by the medication, although often more severe.
What should I avoid while using daunorubicin?
Daunorubicin can lower the activity of your immune system making you susceptible to infections. Avoid contact with people who have colds, the flu, or other contagious illnesses and do not receive vaccines that contain live strains of a virus (e.g., live oral polio vaccine) during treatment with daunorubicin. In addition, avoid contact with individuals who have recently been vaccinated with a live vaccine. There is a chance that the virus can be passed on to you.
Skin accidentally exposed to daunorubicin should be rinsed thoroughly with soap and warm water.
Daunorubicin side effects
If you experience any of the following serious side effects from daunorubicin, contact your doctor immediately:
an allergic reaction (including difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
decreased bone marrow function and blood problems (extreme fatigue; easy bruising or bleeding; black, bloody or tarry stools; or fever, chills, or signs of infection);
congestive heart failure (difficulty breathing, fluid retention, chest pain);
tissue or vein reactions near the site of administration;
liver damage (abdominal pain, yellowing of the skin or eyes);
nausea, vomiting, diarrhea, or loss of appetite;
inflamation or sores inside the mouth, throat, or intestines;
rash, itching, or hives;
fever, chills, or other signs of infection; or
increased levels of uric acid in the body (joint pain and stiffness).
Other, less serious side effects may be more likely to occur. Continue taking daunorubicin and talk to your doctor if you experience:
temporary hair loss; or
red colored urine for 1 or 2 days following a dose.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Daunorubicin Dosing Information
Usual Adult Dose for Acute Nonlymphocytic Leukemia:
Usual Adult Dose for Acute Lymphocytic Leukemia:
For Remission Induction:
45 mg/m²/day IV on days 1, 2, and 3 (along with vincristine, prednisone, and L-asparginase therapy)
Usual Geriatric Dose for Acute Nonlymphocytic Leukemia:
>=60 years: 30 mg/m² IV over 2-5 minutes once a day on days 1, 2, and 3 for the first course and on days 1 and 2 for subsequent courses) with cytosine arabinoside (ara-C) intravenously once a day (usually for 7 days for the first course and 5 days for subsequent courses) as remission induction therapy.
Usual Pediatric Dose for Acute Myeloid Leukemia:
As a part of combination therapy: Induction:
30 to 60 mg/m2/day by continuous IV infusion on days 1 to 3 of cycle
or
20 mg/m2/day for 4 days every 14 days
Usual Pediatric Dose for Acute Lymphocytic Leukemia:
Acute Lymphocytic Leukemia combination therapy: Remission Induction:
1 mg/kg per protocol with frequency dependent on regimen employed.
> 2 years or >0.5 m2:
25 mg/m² IV on day 1 every week (along with vincristine and prednisolone therapy). Generally complete remission will be obtained after 4 courses of therapy. If needed, an additional 1 or 2 courses of therapy may be administered in an effort to obtain a complete remission.
or
25 to 45 mg/m2 on days 1 and 8 of cycle (as a part of combination chemotherapy)
or
30 to 45 mg/m2/day for 3 days every 3 to 4 weeks
What other drugs will affect daunorubicin?
Do not use daunorubicin without first talking to your doctor if you have had previous treatment with doxorubicin (Adriamycin, Rubex), doxorubicin liposomal (Doxil), daunorubicin (Cerubidine), daunorubicin liposomal (DaunoXome), idarubicin (Idamycin), or mitoxantrone (Novantrone). Because there is a maximum amount of these medications that should be administered to an individual, you may not be able to use daunorubicin.
Before using daunorubicin, tell your doctor if you are taking any of the following drugs:
cyclophosphamide (Cytoxan, Cytoxan Lyophilized, Neosar); or
methotrexate (Folex PFS, Rheumatrex Dose Pack ).
You may not be able to take daunorubicin, or you may require a dosage adjustment or special monitoring during treatment if you are taking any of the medicines listed above.
Do not receive "live" vaccines during treatment with daunorubicin. Administration of a live vaccine may be dangerous during treatment with daunorubicin.
Drugs other than those listed here may also interact with daunorubicin. Talk to your doctor and pharmacist before taking any other prescription or over-the-counter medicines, including herbal products, during treatment with daunorubicin.
More daunorubicin resources
- Daunorubicin Dosage
- Daunorubicin Use in Pregnancy & Breastfeeding
- Daunorubicin Drug Interactions
- Daunorubicin Support Group
- 0 Reviews for Daunorubicin - Add your own review/rating
- daunorubicin Intravenous Advanced Consumer (Micromedex) - Includes Dosage Information
- Cerubidine Prescribing Information (FDA)
- Daunorubicin MedFacts Consumer Leaflet (Wolters Kluwer)
- Daunorubicin Prescribing Information (FDA)
- daunorubicin citrate Monograph (AHFS DI)
Compare daunorubicin with other medications
- Acute Lymphocytic Leukemia
- Acute Myeloid Leukemia
- Acute Nonlymphocytic Leukemia
Where can I get more information?
- Your healthcare provider may have additional information about daunorubicin that you may read.
